- Home
- / Ascendis Pharma
Ascendis Pharma
Stock Price
$104.9
2023-03-24
Market Capitalization
$6 B
2023-03-24
Revenue
€51.2 M
FY, 2022
Ascendis Pharma Summary
Company summary
- Overview
- Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. It utilizes its TransCon technologies to develop treatments for such diseases as growth hormone deficiency (GHD), hypoparathyroidism, cancer, etc.
- Type
- Public
- Status
- Active
- Founded
- 2007
- HQ
- Hellerup, DK | view all locations
- Website
- https://ascendispharma.com
- Cybersecurity rating
- ESG rating
Key people
Flemming Steen Jensen, Executive Vice President, Product Supply and Quality
Vibeke Miller, Executive Vice President, Nonclinical Development and Bioanalysis
Michael Wolff Jensen, Executive Vice President, Chief Legal Officer
LocationsView all
3 locations detected
Hellerup HQ
Denmark
Tuborg Blvd. 12
Palo Alto, CA
United States
1000 Page Mill Rd
Heidelberg, Baden-Württemberg
Germany
584 Im Neuenheimer Feld
Ascendis Pharma Financials
Summary financials
- Revenue (FY, 2022)
- €51.2M
- Gross profit (FY, 2022)
- €40.3M
- Net income (FY, 2022)
- (€583.2M)
- Cash (FY, 2022)
- €427.8M
- EBIT (FY, 2022)
- (€579.5M)
- Enterprise value
- $6.1B
News
Footer menu
Products
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension